AMLX · Amylyx Pharmaceuticals, Inc.
$18.41
+0.31% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-14.3
Dividend yield
—
Beta
-0.20
Avg volume
1M
Employees
0K
2D change
—
5D change
10.80%
10D change
9.80%
30D change
9.56%
60D change
35.82%
MTD change
8.58%
YTD change
61.34%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AMLX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-20
Latest call per bank · past 12 months
Bank of America
Buy$19.00
+3.2% vs priceCitigroup
Buy$20.00
+8.6% vs priceGoldman Sachs
Buy$20.00
+8.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | Mizuho | Maintains | Outperform | $21.00 → $24.00 |
| 2026-06-25 | Guggenheim | Maintains | Buy | $30.00 → $40.00 |
| 2026-04-28 | Mizuho | Maintains | Outperform | $19.00 → $21.00 |
| 2026-03-25 | HC Wainwright & Co. | Reiterates | Buy | $34.00 |
| 2026-03-19 | Guggenheim | Maintains | Buy | $25.00 → $30.00 |
| 2026-03-04 | HC Wainwright & Co. | Maintains | Buy | $28.00 → $34.00 |
| 2026-03-03 | Stifel | Initiates | Buy | $0.00 → $21.00 |
| 2026-02-20 | Bank of America | Maintains | Buy | $15.00 → $19.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 64 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 22.3% above the 50-day MA ($15.98).
- Price vs 200-day MA: Trading 32.5% above the 200-day MA ($14.75).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.06) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($19.55).
AMLX Price Chart
Loading chart for AMLX…
Fundamentals
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.